Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

J App Pharm Sci. 2020; 10(10): 152-166


Approaches for synthesis and chemical modification of non-condensed heterocyclic systems based on 1,3,4-oxadiazole ring and their biological activity: A review

Maryan Lelyukh, Marta Martynets, Myroslava Kalytovska, Iryna Drapak, Stefan Harkov, Taras Chaban, Ihor Chaban, Vasyl Matiychuk.




Abstract
Cited by 26 Articles

1,3,4-Oxadiazole scaffold is one of the most important heterocyclic fragments, which is considered as a perspective building block for drug discovery. Substituted 1,3,4-oxadiazoles had been reported to display a diverse range of pharmacological activities including anticancer, anti-inflammatory, antitubercular, antibacterial, antiviral, antifungal, insecticidal, antioxidant, and analgesic activities. Moreover, the 1,3,4-oxadiazole core is a structural component of approved antiretroviral (Raltegravir), anticancer (Zibotentan), and antihypertensive (Tiodazosin and Nesapidil) drugs. In the present review, we summarized the literature data about the main approaches for obtaining possible directions of structural modification and pharmacological activity of noncondensed heterocyclic systems based on the 1,3,4-oxadiazole ring as promising objects for modern bioorganic and medicinal chemistry.

Key words: synthesis, 1,3,4-oxadiazoles, chemical modification, biological activity






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.